Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease

被引:67
作者
Schneider, Susanne A. [1 ]
Alcalay, Roy N. [2 ]
机构
[1] Ludwig Maximilians Univ Munchen, Dept Neurol, Marchioninistr 15, D-81377 Munich, Germany
[2] Columbia Univ, Dept Neurol, Med Ctr, New York, NY USA
关键词
Genetic Parkinson's disease; SNCA; GBA; LRRK2; Kinase inhibitor; Small molecule compounds; Venglustat; Ambroxol; Clinical trial; TORC1; inhibitor; Superprecision medicine; GAUCHER-DISEASE; GLUCOCEREBROSIDASE MUTATIONS; THERAPEUTIC STRATEGY; RISK LOCI; LRRK2; IDENTIFICATION; METAANALYSIS; ASSOCIATION; PENETRANCE; INHIBITORS;
D O I
10.1007/s00415-020-09705-7
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In recent years, numerous clinical trials for disease modification in Parkinson's disease (PD) have failed, possibly because of a "one-size-fits all" approach. Alternatively, a precision medicine approach, which customises treatments based on patients' individual genotype, may help reach disease modification. Here, we review clinical trials that target genetic forms of PD, i.e., GBA-associated and LRRK2-associated PD. In summary, six ongoing studies which explicitely recruit GBA-PD patients, and two studies which recruit LRRK2-PD patients, were identified. Available data on mechanisms of action, study design, and challenges of therapeutic trials are discussed.
引用
收藏
页码:860 / 869
页数:10
相关论文
共 64 条
[1]  
Abrahams E, 2 BIOM M PERS REPR M
[2]  
Analysis Group Inc, 2017, BIOPH PIP INN THER C
[3]  
[Anonymous], PREV THER PREV IS DE
[4]   LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectives [J].
Atashrazm, Farzaneh ;
Dzamko, Nicolas .
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2016, 8 :177-189
[5]  
Baptista MAS, 2018, LRRK2 KINASE INHIBIT, DOI [10.1101/390815v1, DOI 10.1101/390815V1]
[6]   Advances in GSA-associated Parkinson's disease - Pathology, presentation and therapies [J].
Barkhuizen, Melinda ;
Anderson, David G. ;
Grobler, Anne F. .
NEUROCHEMISTRY INTERNATIONAL, 2016, 93 :6-25
[7]   Frequency of Loss of Function Variants in LRRK2 in Parkinson Disease [J].
Blauwendraat, Cornelis ;
Reed, Xylena ;
Kia, Demis A. ;
Gan-Or, Ziv ;
Lesage, Suzanne ;
Pihistrom, Lasse ;
Guerreiro, Rita ;
Gibbs, J. Raphael ;
Sabir, Marya ;
Ahmed, Sarah ;
Ding, Jinhui ;
Alcalay, Roy N. ;
Hassin-Baer, Sharon ;
Pittman, Alan M. ;
Brooks, Janet ;
Edsall, Connor ;
Hernandez, Dena G. ;
Chung, Sun Ju ;
Goldwurm, Stefano ;
Toft, Mathias ;
Schulte, Claudia ;
Bras, Jose ;
Wood, Nicholas W. ;
Brice, Alexis ;
Morris, Huw R. ;
Scholz, Sonja W. ;
Nalls, Mike A. ;
Singleton, Andrew B. ;
Cookson, Mark R. .
JAMA NEUROLOGY, 2018, 75 (11) :1416-1422
[8]  
Centogene AG, 2018, CENTOGENE DENALI THE
[9]   Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease [J].
Clark, L. N. ;
Ross, B. M. ;
Wang, Y. ;
Mejia-Santana, H. ;
Harris, J. ;
Louis, E. D. ;
Cote, L. J. ;
Andrews, H. ;
Fahn, S. ;
Waters, C. ;
Ford, B. ;
Frucht, S. ;
Ottman, R. ;
Marder, K. .
NEUROLOGY, 2007, 69 (12) :1270-1277
[10]  
Clark LN, 2009, ARCH NEUROL-CHICAGO, V66, P578, DOI 10.1001/archneurol.2009.54